Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Jing Xue, Xia Yan, Qin Ding, Nan Li, Menghan Wu & Jianbo Song. (2023) Effect of neoadjuvant chemotherapy on the immune microenvironment of gynaecological tumours. Annals of Medicine 55:2.
Read now
Read now
Nilanchali Singh, Aarthi S Jayraj, Avir Sarkar, Trishala Mohan, Amlin Shukla & Prafull Ghatage. (2023) Pharmacotherapeutic treatment options for recurrent epithelial ovarian cancer. Expert Opinion on Pharmacotherapy 24:1, pages 49-64.
Read now
Read now
Yan-Li Hou, Di-Ya Wang, Jie-Xuan Hu, Ru-Yue Tian, Wei Wang, Qiang Su, Hongyang Li & Yan-Ling Wang. (2022) Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. Ocular Immunology and Inflammation 30:6, pages 1449-1459.
Read now
Read now
Innocenza Palaia, Federica Tomao, Carolina Maria Sassu, Lucia Musacchio & Pierluigi Benedetti Panici. (2020) Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches. OncoTargets and Therapy 13, pages 6109-6129.
Read now
Read now
Giusi Santangelo, Giuseppe Caruso, Innocenza Palaia, Federica Tomao, Giorgia Perniola, Violante Di Donato, Margherita Fischetti, Ludovico Muzii & Pierluigi Benedetti Panici. (2020) The emerging role of precision medicine in the treatment of ovarian cancer. Expert Review of Precision Medicine and Drug Development 5:4, pages 283-297.
Read now
Read now
Julie M. Collins & James L. Gulley. (2019) Product review: avelumab, an anti-PD-L1 antibody. Human Vaccines & Immunotherapeutics 15:4, pages 891-908.
Read now
Read now
Articles from other publishers (52)
Ran Ren, Xin Chang, Cong Chen, Hao Yu & Lu Han. (2023) VISTA as a prospective immune checkpoint in gynecological malignant tumors: A review of the literature. Open Medicine 18:1.
Crossref
Crossref
Ana C. Veneziani, Eduardo Gonzalez-Ochoa, Husam Alqaisi, Ainhoa Madariaga, Gita Bhat, Marjan Rouzbahman, Suku Sneha & Amit M. Oza. (2023) Heterogeneity and treatment landscape of ovarian carcinoma. Nature Reviews Clinical Oncology 20:12, pages 820-842.
Crossref
Crossref
Jian Xiong, Yiyuan Fu, Jiezheng Huang, Yibin Wang, Xiaolong Jin, Xiaoyan Wan, Liu Huang & Zheng Huang. (2023) Metabolic and senescence characteristics associated with the immune microenvironment in ovarian cancer. Frontiers in Endocrinology 14.
Crossref
Crossref
Akhil Raj, Amal Babu, Vinoth Kumar Kothandan, In-Kyu Park & Seung Rim Hwang. (2023) Development of nano-immunotherapy for cancer treatment: achievements and scopes. Journal of Pharmaceutical Investigation 53:6, pages 827-844.
Crossref
Crossref
Nicolas Boisgerault & Philippe Bertrand. (2023) Inside PD-1/PD-L1,2 with their inhibitors. European Journal of Medicinal Chemistry 256, pages 115465.
Crossref
Crossref
Rebecca Newhouse, Ellen Nelissen, Karim Hussien El-Shakankery, Ewelina Rogozińska, Esme Bain, Susana Veiga & Jo Morrison. (2023) Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2023:7.
Crossref
Crossref
Jonathan Charles, Andrea Vrionis, Arian Mansur, Trevor Mathias, Jamil Shaikh, Aaron Ciner, Yixing Jiang & Nariman Nezami. (2023) Potential Immunotherapy Targets for Liver-Directed Therapies, and the Current Scope of Immunotherapeutics for Liver-Related Malignancies. Cancers 15:9, pages 2624.
Crossref
Crossref
Yuan He, Pengyong Han, Chuang Chen, Shuzhe Xie, Huiqing Zhang, Yingming Song, Hao Hu, Qiang Zhao & Changhong Lian. (2021) circPTPN22 attenuates immune microenvironment of pancreatic cancer via STAT3 acetylation. Cancer Gene Therapy 30:4, pages 559-566.
Crossref
Crossref
Sue Cheeseman, Bethany Levick, Will Sopwith, Hayley Fenton, Eun Ji Nam, DongKyu Kim, Subin Lim, Elodie Martin, Jean-Sébastien Frenel, François Bocquet, Paul Kubelac, Patriciu Achimas-Cadariu, Catalin Vlad, Marion Chevrier, Roman Rouzier, Matthieu Carton, Joana Savva-Bordalo, Marta Magalhães, Marina Borges, Andrea Wolf, Sven Becker, Nicolas Niklas, Mariana Guergova-Kuras & Geoff Hall. (2023) Ovarian Real-World International Consortium (ORWIC): A multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes. Frontiers in Oncology 13.
Crossref
Crossref
Munawaer Muaibati, Abasi Abuduyilimu, Tao Zhang, Yun Dai, Ruyuan Li, Fanwei Huang, Kexin Li, Qing Tong, Xiaoyuan Huang & Liang Zhuang. (2023) Efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer. Expert Reviews in Molecular Medicine 25.
Crossref
Crossref
Michael J. Birrer & Brandon Roane. 2023. DiSaia and Creasman Clinical Gynecologic Oncology. DiSaia and Creasman Clinical Gynecologic Oncology
489
505.e5
.
Ying Zhou, Xiaoyu Cai, Linwen Wu & Nengming Lin. (2022) Comparative glycoproteomics study on the surface of SKOV3 versus IOSE80 cell lines. Frontiers in Chemistry 10.
Crossref
Crossref
Hongling Peng, Xiang He & Qiao Wang. (2022) Immune checkpoint blockades in gynecological cancers: A review of clinical trials. Acta Obstetricia et Gynecologica Scandinavica 101:9, pages 941-951.
Crossref
Crossref
Maximilian Haist, Volker Mailänder & Matthias Bros. (2022) Nanodrugs Targeting T Cells in Tumor Therapy. Frontiers in Immunology 13.
Crossref
Crossref
Camila Bragança Xavier, Carlos Diego Holanda Lopes, Guilherme Harada, Eduardo Dante Bariani Peres, Artur Katz & Denis Leonardo Jardim. (2022) Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis. Translational Oncology 19, pages 101383.
Crossref
Crossref
Michelle McMullen, Ainhoa Madariaga & Stephanie Lheureux. (2021) New approaches for targeting platinum-resistant ovarian cancer. Seminars in Cancer Biology 77, pages 167-181.
Crossref
Crossref
Anaïs Wambecke, Mohammad Ahmad, Pierre‐Marie Morice, Bernard Lambert, Louis‐Bastien Weiswald, Mégane Vernon, Nicolas Vigneron, Edwige Abeilard, Emilie Brotin, Martin Figeac, Pascal Gauduchon, Laurent Poulain, Christophe Denoyelle & Matthieu Meryet‐Figuiere. (2021) The lncRNA ‘UCA1’ modulates the response to chemotherapy of ovarian cancer through direct binding to miR‐27a‐5p and control of UBE2N levels. Molecular Oncology 15:12, pages 3659-3678.
Crossref
Crossref
Junzo Hamanishi, Nobuhiro Takeshima, Noriyuki Katsumata, Kimio Ushijima, Tadashi Kimura, Satoshi Takeuchi, Koji Matsumoto, Kimihiko Ito, Masaki Mandai, Hidekatsu Nakai, Noriaki Sakuragi, Hidemichi Watari, Nobutaka Takahashi, Hidenori Kato, Kosei Hasegawa, Kan Yonemori, Mika Mizuno, Kazuhiro Takehara, Hitoshi Niikura, Takashi Sawasaki, Sari Nakao, Toshiaki Saito, Takayuki Enomoto, Satoru Nagase, Nao Suzuki, Takashi Matsumoto, Eiji Kondo, Kenzo Sonoda, Satomi Aihara, Yoichi Aoki, Aikou Okamoto, Hirokuni Takano, Hiroshi Kobayashi, Hisamori Kato, Yoshito Terai, Akira Takazawa, Yusuke Takahashi, Yoshinobu Namba, Daisuke Aoki, Keiichi Fujiwara, Toru Sugiyama & Ikuo Konishi. (2021) Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). Journal of Clinical Oncology 39:33, pages 3671-3681.
Crossref
Crossref
Anna Pawłowska, Agnieszka Kwiatkowska, Dorota Suszczyk, Agata Chudzik, Rafał Tarkowski, Bartłomiej Barczyński, Jan Kotarski & Iwona Wertel. (2021) Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients. International Journal of Molecular Sciences 22:21, pages 11563.
Crossref
Crossref
Marija Gjorgoska & Tea Lanišnik Rižner. (2021) Estrogens and the Schrödinger’s Cat in the Ovarian Tumor Microenvironment. Cancers 13:19, pages 5011.
Crossref
Crossref
Jitka Fucikova, An Coosemans, Sandra Orsulic, David Cibula, Ignace Vergote, Lorenzo Galluzzi & Radek Spisek. (2021) Immunological configuration of ovarian carcinoma: features and impact on disease outcome. Journal for ImmunoTherapy of Cancer 9:10, pages e002873.
Crossref
Crossref
Wenxiang Zhang, Xiangyi Kong, Bolun Ai, Zhongzhao Wang, Xiangyu Wang, Nianchang Wang, Shan Zheng, Yi Fang & Jing Wang. (2021) Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy. Frontiers in Oncology 11.
Crossref
Crossref
Xiao-xiao Guo, Zhen-hu Guo, Jing-song Lu, Wen-sheng Xie, Qiu-zi Zhong, Xiao-dan Sun, Xiu-mei Wang, Jian-ye Wang, Ming Liu & Ling-yun Zhao. (2021) All-purpose nanostrategy based on dose deposition enhancement, cell cycle arrest, DNA damage, and ROS production as prostate cancer radiosensitizer for potential clinical translation. Nanoscale 13:34, pages 14525-14537.
Crossref
Crossref
Tina Laga, Ignace Vergote & Els Van Nieuwenhuysen. (2021) Immunotherapy in rare ovarian cancer. Current Opinion in Oncology 33:5, pages 447-456.
Crossref
Crossref
Yu Rebecca Miao, Kaushik N. Thakkar, Jin Qian, Mihalis S. Kariolis, Wei Huang, Saravanan Nandagopal, Teddy Tat Chi Yang, Anh N. Diep, Gerald Maxwell Cherf, Yu Xu, Eui Jung Moon, Yiren Xiao, Haizea Alemany, Tiane Li, Wenhua Yu, Bo Wei, Erinn B. Rankin & Amato J. Giaccia. (2021) Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer. Clinical Cancer Research 27:15, pages 4435-4448.
Crossref
Crossref
Chuanmeng ZhangJie XuJun YeXiaohong Zhang. (2021) Prognostic value of HHLA2 expression in solid tumors. Medicine 100:30, pages e26789.
Crossref
Crossref
Jiexuan Hu, Ruyue Tian, Yingjie Ma, Hongchao Zhen, Xiao Ma, Qiang Su & Bangwei Cao. (2021) Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis. Frontiers in Oncology 11.
Crossref
Crossref
Lan Mu, Yan Song, Kuaile Zhao, Ying Liu, Qingxia Fan, Xi Wang, Qun Li, Xiaopeng Wang & Jing Huang. (2021)
SHR‐1316
, an
anti‐PD‐L1
antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase
2
study
. Thoracic Cancer 12:9, pages 1373-1381.
Crossref
Crossref
Kathryn Miller & Dmitriy Zamarin. (2021) Challenges and Opportunities for Immunotherapy in Gynecologic Cancer. Advances in Oncology 1, pages 113-123.
Crossref
Crossref
Jamal Majidpoor & Keywan Mortezaee. (2021) The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. Clinical Immunology 226, pages 108707.
Crossref
Crossref
Caroline Eymerit-Morin, Anna Ilenko, Thomas Gaillard, Justine Varinot, Eva Compérat, Sofiane Bendifallah & Emile Darai. (2021) PD-L1 expression with QR1 and E1L3N antibodies according to histological ovarian cancer subtype: A series of 232 cases. European Journal of Histochemistry 65:1.
Crossref
Crossref
Hiroshi Nishio, Takashi Iwata & Daisuke Aoki. (2021) Current status of cancer immunotherapy for gynecologic malignancies. Japanese Journal of Clinical Oncology 51:2, pages 167-172.
Crossref
Crossref
Yingchun Li, Zheng Zhao, Dan Sun & Yanfei Li. (2020) Novel long noncoding RNA LINC02323 promotes cell growth and migration of ovarian cancer via TGF‐β receptor 1 by miR‐1343‐3p. Journal of Clinical Laboratory Analysis 35:2.
Crossref
Crossref
Fabian Trillsch, Sven Mahner, Bastian Czogalla, Miriam Rottmann, Radoslav Chekerov, Elena Ioana Braicu, Gülten Oskay-Öczelik, Pauline Wimberger, Rolf Richter & Jalid Sehouli. (2021) Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group. Journal of Gynecologic Oncology 32:3.
Crossref
Crossref
Khalid El Bairi, Ouissam Al Jarroudi & Said Afqir. 2021. Ovarian Cancer Biomarkers. Ovarian Cancer Biomarkers
59
133
.
Tilahun Ayane Debele, Cheng-Fa Yeh & Wen-Pin Su. (2020) Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators. Cancers 12:12, pages 3773.
Crossref
Crossref
Erin G. Hartnett, Julia Knight, Mackenzy Radolec, Ronald J. Buckanovich, Robert P. Edwards & Anda M. Vlad. (2020) Immunotherapy Advances for Epithelial Ovarian Cancer. Cancers 12:12, pages 3733.
Crossref
Crossref
Elizabeth K. Lee, Niya Xiong, Su-Chun Cheng, William T. Barry, Richard T. Penson, Panagiotis A. Konstantinopoulos, Mark A. Hoffman, Neil Horowitz, Don S. Dizon, Elizabeth H. Stover, Alexi A. Wright, Susana M. Campos, Carolyn Krasner, Stephanie Morrissey, Christin Whalen, Roxanne Quinn, Ursula A. Matulonis & Joyce F. Liu. (2020) Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecologic Oncology 159:1, pages 72-78.
Crossref
Crossref
Mohamed A. Alfaleh, Hashem O. Alsaab, Ahmad Bakur Mahmoud, Almohanad A. Alkayyal, Martina L. Jones, Stephen M. Mahler & Anwar M. Hashem. (2020) Phage Display Derived Monoclonal Antibodies: From Bench to Bedside. Frontiers in Immunology 11.
Crossref
Crossref
Giorgio Bogani, Salvatore Lopez, Mara Mantiero, Monika Ducceschi, Sara Bosio, Simona Ruisi, Giuseppe Sarpietro, Rocco Guerrisi, Claudia Brusadelli, Andrea Dell'Acqua, Violante Di Donato & Francesco Raspagliesi. (2020) Immunotherapy for platinum-resistant ovarian cancer. Gynecologic Oncology 158:2, pages 484-488.
Crossref
Crossref
Lana E. Kandalaft, Kunle Odunsi & George Coukos. (2020) Immune Therapy Opportunities in Ovarian Cancer. American Society of Clinical Oncology Educational Book:40, pages e228-e240.
Crossref
Crossref
Olivia Le Saux, Bertrand Dubois, Marc-Henri Stern, Magali Terme, Eric Tartour, Jean-Marc Classe, Nicolas Chopin, Olivier Trédan, Christophe Caux & Isabelle Ray-Coquard. (2020) Les avancées actuelles de l’immunothérapie dans le cancer de l’ovaire. Bulletin du Cancer 107:4, pages 465-473.
Crossref
Crossref
Ewelina Grywalska, Małgorzata Sobstyl, Lechosław Putowski & Jacek Roliński. (2019) Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors. International Journal of Molecular Sciences 20:19, pages 4705.
Crossref
Crossref
Lana E. Kandalaft, Kunle Odunsi & George Coukos. (2019) Immunotherapy in Ovarian Cancer: Are We There Yet?. Journal of Clinical Oncology 37:27, pages 2460-2471.
Crossref
Crossref
Eric Pujade-Lauraine, Susana Banerjee & Sandro Pignata. (2019) Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives. Journal of Clinical Oncology 37:27, pages 2437-2448.
Crossref
Crossref
Daniela Luvero, Francesco Plotti, Alessia Aloisia, Roberto Montera, Corrado Terranova, Carlo De Cicco Nardone, Giuseppe Scaletta, Salvatore Lopez, Andrea Miranda, Stella Capriglione, Alessandra Gatti, Pierluigi Benedetti Panici & Roberto Angioli. (2019) Ovarian cancer relapse: From the latest scientific evidence to the best practice. Critical Reviews in Oncology/Hematology 140, pages 28-38.
Crossref
Crossref
Elisa Schmoeckel, Sophie Hofmann, Daniel Fromberger, Miriam Rottmann, Beate Luthardt, Alexander Burges, Udo Jeschke, Thomas Kirchner, Sigurd F. Lax & Doris Mayr. (2019) Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma. Virchows Archiv 474:5, pages 599-608.
Crossref
Crossref
Rebecca Ann Previs & Angeles Alvarez Secord. (2019) Ovarian Cancer. Obstetrics and Gynecology Clinics of North America 46:1, pages 67-88.
Crossref
Crossref
Mary L. Disis, Matthew H. Taylor, Karen Kelly, J. Thaddeus Beck, Michael Gordon, Kathleen M. Moore, Manish R. Patel, Jorge Chaves, Haeseong Park, Alain C. Mita, Erika P. Hamilton, Christina M. Annunziata, Hans Juergen Grote, Anja von Heydebreck, Jaspreet Grewal, Vikram Chand & James L. Gulley. (2019) Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer. JAMA Oncology 5:3, pages 393.
Crossref
Crossref
A Pawłowska, D Suszczyk, K Okła, B Barczyński, J Kotarski & I Wertel. (2019) Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment. Clinical and Experimental Immunology 195:3, pages 334-344.
Crossref
Crossref
Albert A. De Vera, Pranav Gupta, Zining Lei, Dan Liao, Silpa Narayanan, Qiuxu Teng, Sandra E. Reznik & Zhe-Sheng Chen. (2019) Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo. Cancer Letters 442, pages 91-103.
Crossref
Crossref
Ying L. Liu & Dmitriy Zamarin. (2018) Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers. Current Oncology Reports 20:12.
Crossref
Crossref